• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Newsletter Sign Up
Contact
  • Home
  • News
  • News
  • NMPA Registration in China
  • Medical Device
  • Medical device clinical trial data submission – New registration requirements issued

Medical device clinical trial data submission – New registration requirements issued

Clinical Trials GMP management
Monday, 20 December 2021 / Published in Medical Device, News, NMPA Registration in China

Medical device clinical trial data submission – New registration requirements issued

Medical device clinical trial data submission in China should now refer to the the technical review guidelines issued (No.91 – 2021) by the National Medical Products Administration (NMPA) on November 25, 2021.

Highlights

  • Medical Device Clinical Trial Data Submission
    • Scope of application: Applicable to clinical trials of medical devices for the purpose of product registration, including overseas clinical trials; Not applicable to clinical trials of In Vitro Diagnostics.
    • Basic principles of data submission: Authenticity, traceability and readability.
    • Submission form requirements: Clinical trial data of medical devices usually include original database, analytical database, explanatory documents and procedure code. The guideline provides requirements and provisions on the specific format and content of each application data. Applicants are encouraged to submit Data in accordance with the Clinical Data Interchange Standards Consortium (CDISC) Standards. The original database, analysis database, illustrative files, and program code are placed in four separate folders.
  • In Vitro Diagnostics Clinical Trial Data Submission
    • Scope of application: Applicable to in vitro diagnostics clinical trial carried out for the purpose of product registration, including overseas clinical trial.
    • Basic principles of data submission: authenticity, traceability, readability and comprehensiveness of data.
    • Requirements of Clinical trial database contents: In general, clinical trial database content shall include information about subjects and test information of clinical trial samples. The guideline specifies data information that should be included in different types of clinical trial design.
    • Requirements of submission form: Applications relating to in vitro diagnostic clinical trial data usually include the original database, analytical database, explanatory documentation and procedure code (if any). The guidelines specify the specific format and content of each application. Applicants are encouraged to submit Data in accordance with the Clinical Data Interchange Standards Consortium (CDISC) Standards. The original database, analysis database, illustrative files, and program code (if any) should be placed in four separate folders.

By Alice Liu and Jacky Li. Cisema regularly support clinical trials in China as a CRO. For our clinical trial protocol and preparatory studies, or more details about full clinical trial support in China, please inform us.

Tagged under: clinical trial data, Clinical Trials

What you can read next

Cisema Webinar on Drug Registration Pathways in China
supervision of medical device business
Supervision of Medical Device Business Operation in China – 2022 Regulatory Updates
China SAMR 3 Stipulation Scheme Unveiled

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • Submission of safety information for cosmetics ingredients

    Submission of safety information for cosmetics raw materials – Draft guidelines issued

    Submission of safety information for cosmetics ...
  • avoid animal testing in Chinaweb-2023

    How to avoid animal testing in China for cosmetics | Cisema Webinar

    China’s beauty and cosmetic market has be...
  • guidelines for medical devices registration

    Guidelines for medical devices registration in China – New development plans in 2023

    Guidelines for medical devices registration in ...
  • China DMF of API

    China DMF of API, Excipient & Packaging Materials: Market & Regulatory | Cisema Webinar

    “China DMF of API, Excipient & Packag...
  • pre-phase III drug clinical trial meeting guidelines

    Pre-phase III drug clinical trial meeting guidelines released

    Pre-phase III drug clinical trial meeting guide...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP